NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
Clinical Trials
100 trialsNCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT02151123 2025-09-26
Metabiomics Colon Cancer Clinical Research Study
Metabiomics Corp
Withdrawn
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT04571710 2025-07-24
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT04889495 2025-03-19
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT00756782 2024-09-04
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
Taiho Oncology, Inc.
Phase 2 Withdrawn
NCT06518538 2024-08-15
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT06284226 2024-04-16
CCT-ANK-11
Beijing Kejing Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT03127124 2024-04-02
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
NantPharma, LLC
Phase 1/2 Withdrawn
NCT04276909 2024-03-13
Feasibility Study of LUM Imaging System for Pancreatic Cancer
Lumicell, Inc.
Phase NA Withdrawn
NCT05292443 2024-02-23
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Geneplus-Beijing Co. Ltd.
Withdrawn
NCT05465590 2023-12-21
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Mainline Biosciences, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT05702385 2023-12-07
Clinical Utility Study for Exo-PDAC
Qure Healthcare, LLC
Phase NA Withdrawn
NCT05641922 2023-11-27
PANORAMA2
Techsomed Medical Technologies LTD
Phase NA Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT05821582 2023-10-12
Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
Sanguine Biosciences
Withdrawn
NCT05043987 2023-09-07
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
Phase 1 Withdrawn
NCT05411679 2023-06-12
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Ellipses Pharma
Phase 2 Withdrawn
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT04811833 2023-04-05
GASTROMO
Aesculap AG
Withdrawn
NCT05183295 2023-04-03
Medical Food for the Dietary Management of Metastatic Colorectal Cancer
Faeth Therapeutics
Phase NA Withdrawn
NCT01792882 2023-02-28
GBCPRT0008
Global BioClinical
Withdrawn
NCT05730673 2023-02-17
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
CytoDyn, Inc.
Phase 2 Withdrawn
NCT05628545 2023-01-18
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Guangdong GD Kongming Biotech LLC
Phase 1/2 Withdrawn
NCT05041972 2022-09-13
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
Phase 2 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT03634683 2022-06-30
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Lion TCR Pte. Ltd.
Phase 1/2 Withdrawn
NCT05104905 2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT04231929 2022-03-28
BIOPEARL-FIRST
Terumo Europe N.V.
Phase NA Withdrawn
NCT04123574 2022-02-24
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
BioXcel Therapeutics Inc
Phase EARLY_PHASE1 Withdrawn
NCT05181865 2022-02-07
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Flame Biosciences
Phase 1/2 Withdrawn
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT04499352 2021-11-15
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
Boehringer Ingelheim
Phase 2 Withdrawn
NCT04315311 2021-11-08
Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer
AbbVie
Phase 4 Withdrawn
NCT01510561 2021-08-19
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Gilead Sciences
Phase 1 Withdrawn
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn